The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan
Avidity for the tracer typically decreases with time since radiation therapy (PMID 30317847). This helps separating the radiation-induced avidity from relapse of the underlying malignant condition
Publications
(18)F-FDG PET/CT in Patients with Parenchymal Changes Attributed to Radiation Pneumonitis.
Molecular imaging and radionuclide therapy. 2018;27(3):107-112
Assessing the usefulness of 18F-fluorodeoxyglucose PET-CT scan after stereotactic body radiotherapy for early-stage non-small cell lung cancer.
Chest. 2014;146(2):406-411
Matsuo Y, Nakamoto Y, Nagata Y, Shibuya K, Takayama K, Norihisa Y, Narabayashi M, Mizowaki T, Saga T, Higashi T, Togashi K, Hiraoka M
Characterization of FDG-PET images after stereotactic body radiation therapy for lung cancer.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2010;97(2):200-4